The Upstate Global Health Institute is currently seeking participants with HIV, who are being treated with Trogarzo (Ibalizumab). This registry study will look at routine healthcare data for 3 years to see how effective and long lasting Trogarzo is, when used in combination with other drugs used to treat adults living with HIV, who have tried multiple HIV medications. No study medications will be administered and no medical procedures will be performed as part of this study. All study information will be collected as part of your routine healthcare.

The Upstate Global Health Institute is enrolling participants, aged 18-70, who are living with HIV and on stable ART (antiretroviral treatment). The purpose of this study is to test two investigational drugs, budigalmab and ABBV-382 and learn what kinds of side effects or other safety problems might be seen when the combination is given. Also to learn if budigalimab and/or ABBV-382 can help the body control the HIV viral load after ART has been stopped. Your participation in this study may include approximately 17 study visits to the research center and 8 phone call visits. The study duration is approximately 57 weeks.

This is an expanded use protocol for patients diagnosed with a Mycobacterium avium complex (MAC). Sponsored by Novartis, the purpose of this program is to make clofazimine available to appropriate patients following clinical presentation.

The Upstate Global Health Institute is seeking participants who have recently been diagnosed with Lyme disease. This research study is investigating whether an investigational new blood test, called LIASON Lyme Detect, can determine whether the germ that causes Lyme disease is detected sooner than conventional diagnostic test. Currently available blood test for Lyme disease can fail to confirm the illness during early infection.

The Upstate Global Health Institute is currently seeking healthy participants 18-55 for a dengue fever clinical trial. Dengue fever is a mosquito-borne illness caused by a virus that impacts an estimated 100 million people each year. A certain type of mosquito transmits the virus. When a mosquito carrying dengue virus bites someone, he or she can get sick with a dengue infection. These infections can be very mild, with little or no symptoms, but may cause fevers, severe headache, nausea, vomiting, muscle and joint pains, pain behind the eyes, and skin rash. An antiviral medication against Dengue has been developed, which is an experimental new drug that is being studied to prevent and treat dengue illness. The goal of this study is to see how well the drug works to prevent or treat dengue infection and to observe the effectiveness of the drug.

The Global Health Institute is conducting a COVID surveillance among healthcare workers from SUNY Upstate Medical University to improve the understanding of infection and disease risk. The purpose of this study is to define the incidence and clinical spectrum of COVID-19 in a group of healthcare workers over one respiratory virus season. We are trying to better understand who gets sick and who does not, and once someone is infected how long they could infect someone else. We also want to know how people's immune systems respond to vaccination, if they choose to do so, and how this impacts the rest of COVID-19 during the fall and winter.

The Upstate Global Health Institute is currently seeking participants who have a history of prior well-defined or probable Lyme disease infection and meet the definition of Post-Treatment Lyme disease Syndrome (PTLDS). This research is being done to see if using an FDA approved drug, Cefriaxone, for Lyme disease is safe and well-tolerated on a 5-day dosing schedule.